This randomized controlled trial looked at patients with chronic kidney disease who were undergoing hemodialysis. The researchers gave some participants three capsules of omega-3 fatty acids totaling 3 grams per day for two months. Other participants took placebo capsules containing medium-chain triglyceride oil instead. The main goal was to see if the omega-3s would lower specific inflammatory markers in the blood, specifically C-reactive protein and interleukin-6.
The study found no statistically significant differences between the two groups. In the omega-3 group, C-reactive protein levels increased from 9.86 to 11.46 mg/L. In the control group, levels rose from 5.24 to 5.61 mg/L. Interleukin-6 levels also rose in both groups, with no meaningful difference between them.
No adverse events or safety concerns were reported during the short follow-up period. However, the study authors note that short-term supplementation is not sufficient to reduce systemic inflammation in these patients. Larger trials with longer durations are warranted to understand the full picture. Readers should take away that a two-month course of omega-3s may not be enough to lower inflammatory markers in this specific population.
